NS Pharma Reports 4.5-Year Duchenne Trial Data as Rare Disease Pipeline Expands on Multiple Fronts
SHERIDAN, WYOMING – April 14, 2026 – NS Pharma, a US-based biopharmaceutical company and subsidiary of Japan's Nippon Shinyaku Co., Ltd., has presented 4.5 years of clinical trial data for its Duchenne muscular dystrophy candidate Brogidirsen — the latest in a series of advances from a pipeline targeting multiple rare diseases. The data was shared at the 2026 MDA Clinical & Scientific Conference in early March, building on results first presented at a major international neuromuscular conference in late 2025. A second DMD compound separately earned FDA Orphan Drug Designation in September 2025, and NS Pharma is simultaneously running a global Phase 2 trial for NS-229, its candidate for a rare inflammatory disease called EGPA. Taken together, these developments mark a significant stretch of progress for a company whose research touches some of the most underserved patient communities in medicine.